All In Biotech

Drug Trial Radar · NCT05766501

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

641

Actual

Start

Mar 17, 2023

Primary completion

Oct 16, 2025

Study completion Sep 6, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.

Conditions

  • HIV Infection

Interventions

  • DOR/ISLDrug

    FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with One or More Adverse Event (AE)Time frame: Up to 96 Weeks
  2. Percentage of participants who Discontinue Study Intervention Due to an AETime frame: Up to 96 Weeks

Locations

95 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 3104)

    Birmingham, Alabama

  • Pueblo Family Physicians ( Site 3102)

    Phoenix, Arizona

  • Pacific Oaks Medical Group ( Site 3123)

    Beverly Hills, California

  • Kaiser Permanente ( Site 3124)

    Los Angeles, California

  • Ruane Clinical Research Group, Inc ( Site 3126)

    Los Angeles, California

  • Mills Clinical Research ( Site 3114)

    Los Angeles, California

  • University of California Davis Health-Internal Medicine: Infectious Diseases ( Site 3137)

    Sacramento, California

  • Georgetown University Medical Center ( Site 3130)

    Washington D.C., District of Columbia

  • Therafirst Medical Center ( Site 3110)

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center ( Site 3117)

    Ft. Pierce, Florida

  • AHF The Kinder Medical Group ( Site 3108)

    Miami, Florida

  • Floridian Clinical Research, LLC ( Site 3133)

    Miami Lakes, Florida

  • Orlando Immunology Center ( Site 3106)

    Orlando, Florida

  • Bliss Healthcare Services ( Site 3115)

    Orlando, Florida

  • CAN Community Health - Sarasota ( Site 3118)

    Sarasota, Florida

  • Triple O Research Institute, P.A ( Site 3116)

    West Palm Beach, Florida

  • Augusta University-Infectious Diseases ( Site 3135)

    Augusta, Georgia

  • Infectious Disease Specialists of Atlanta ( Site 3128)

    Decatur, Georgia

  • Mercer university, Department of internal medicine-Clinical Research ( Site 3129)

    Macon, Georgia

  • Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 3105)

    Savannah, Georgia

  • KC CARE Health Center ( Site 3103)

    Kansas City, Missouri

  • ID Care ( Site 3131)

    Hillsborough, New Jersey

  • Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center ( Site 3134)

    New York, New York

  • Penn Medicine: University of Pennsylvania Health System-Perelman Center for Advanced Medicine ( Site

    Philadelphia, Pennsylvania

  • St Hope Foundation ( Site 3121)

    Bellaire, Texas

  • North Texas Infectious Diseases Consultants, P.A ( Site 3100)

    Dallas, Texas

  • Texas Centers for Infectious Disease Associates ( Site 3111)

    Fort Worth, Texas

  • The Crofoot Research Center ( Site 3101)

    Houston, Texas

  • DCOL Center for Clinical Research ( Site 3119)

    Longview, Texas

  • Private Practice - Dr. Peter Shalit ( Site 3120)

    Seattle, Washington

  • Multicare Institute for Research and Innovation ( Site 3127)

    Spokane, Washington

  • Helios Salud ( Site 1002)

    Buenos Aires, Argentina

  • Fundación Huésped ( Site 1001)

    Buenos Aires, Argentina

  • Fundación IDEAA ( Site 1005)

    Buenos Aires, Argentina

  • Instituto Oulton ( Site 1004)

    Córdoba, Córdoba Province, Argentina

  • Instituto CAICI SRL ( Site 1003)

    Rosario, Santa Fe Province, Argentina

  • Holdsworth House Medical Practice ( Site 1100)

    Darlinghurst, New South Wales, Australia

  • St Vincent's Hospital-IBAC ( Site 1103)

    Sydney, New South Wales, Australia

  • Holdsworth House Medical Practice - Brisbane ( Site 1101)

    Brisbane, Queensland, Australia

  • Prahran Market Clinic ( Site 1102)

    Melbourne, Victoria, Australia

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.